Gossamer Bio, Inc. — Form SCHEDULE 13D/A
Filed August 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 72/100
What the filing says
Between July 27 and August 24, 2026, D.E. Shaw Co. entities (via Cogence and Valence Portfolios) systematically sold 4,761,689 shares of Gossamer Bio at prices ranging from $0.1434 to $0.2522 per share, totaling approximately $736M in gross proceeds (unaudited). The sales occurred across 44 separate transactions over 19 trading days. This represents a substantial reduction in D.E. Shaw's stake and signals activist selling pressure or liquidity event.
Why this rating
4.76M shares at ~$0.17 avg = ~$810M notional; Gossamer market cap $271M implies Shaw sold ~3x company value equivalent. Material stake reduction signals loss of confidence; creates downward price pressure and overhang.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.